Capella 4055 Assessment 4
Capella 4055 Assessment 4
Name
Capella university
NURS-FPX4055 Optimizing Population Health through Community Practice
Prof. Name
Date
Health Promotion Plan Presentation
Good morning. We appreciate everyone joining today’s session. Our focus is on reducing Human Papillomavirus (HPV) infection among individuals aged 11 to 26 in Schwenksville, Pennsylvania. The session aims to raise awareness about HPV’s cancer connection, the importance of early immunization, and techniques to initiate conversations with healthcare professionals and family about vaccination. The presentation aligns with our mutually developed SMART goals and the preventive aims outlined in Healthy People 2030.
Presentation Roadmap
In this session, we will:
- Share critical facts about HPV, its mode of transmission, and its link to various cancers
- Highlight the importance, safety, and success rate of the HPV vaccine
- Encourage participants to plan for HPV vaccination within 30 days
- Strengthen participants’ ability to discuss HPV vaccination confidently with healthcare providers and loved ones
- Facilitate active engagement through interactive exercises and discussions
- Evaluate learning outcomes and confidence levels via a post-session quiz and feedback survey
Key Information About HPV and Its Cancer Link
HPV is a widespread virus, typically transmitted through sexual contact or close skin-to-skin interaction. In Pennsylvania, only 68.7% of adolescents are fully vaccinated against HPV-related diseases, with even lower rates in rural locations like Schwenksville (48.7%), where the incidence of HPV-related cancers remains elevated (PA.gov, 2025).
High-risk HPV types, particularly strains 16 and 18, are leading causes of cervical, anal, throat, and genital cancers (Huber et al., 2021). Though many HPV infections clear naturally, persistent infections can cause cellular changes that progress to cancer. Vaccination, especially when administered early, is the most effective method to prevent HPV infection and the cancers it may cause.
Benefits of Receiving HPV Vaccination on Time
Timely HPV vaccination significantly lowers the risk of several cancers and genital warts, particularly when administered before the onset of sexual activity around age 11 or 12. Key advantages include:
| Benefit | Description | Reference |
|---|---|---|
| Stronger Immune Response | Vaccinating early leads to a more robust and long-lasting immune reaction. | Hoes et al., 2021 |
| Cervical Cancer Prevention | Early vaccination prevents strains that commonly cause cervical cancer. | Huber et al., 2021 |
| Prevention of Other Cancers | Reduces the risk of cancers like penile, anal, and oropharyngeal. | Cheng et al., 2020 |
| Avoidance of Genital Warts | Helps prevent painful warts that may cause emotional distress. | Xu et al., 2024 |
| Community Protection | Reduces overall HPV transmission, promoting herd immunity. | Xu et al., 2024 |
Strategies for HPV Vaccination Conversations
Discussing HPV immunization with families and providers can be challenging, but effective strategies include:
| Strategy | Explanation | Reference |
|---|---|---|
| Use Credible Facts | Present statistics from trusted sources like the CDC and WHO to counter misinformation. | CDC; Kassymbekova et al., 2023 |
| Ask Informed Questions | Pose thoughtful questions to facilitate meaningful dialogue, such as benefits or concerns. | Kassymbekova et al., 2023 |
| Address Myths Directly | Dispel common misconceptions—like links to promoting sexual activity—by explaining the vaccine’s primary cancer-preventive role. | Kassymbekova et al., 2023 |
SMART Goals Developed with Participants
Our session was designed with specific SMART goals to guide learning and action:
- Knowledge Goal: 90% of participants will correctly identify at least three key HPV facts related to cancer prevention by the end of the session.
- Behavioral Goal: At least 80% of attendees will commit to scheduling their first HPV vaccine dose within the next 30 days.
- Communication Goal: 85% of participants will express greater confidence in discussing the vaccine with providers and family by the end of the session.
These objectives focus on empowerment through education and action for personal and community health improvement.
Evaluation of SMART Goals
The session yielded positive results across most SMART goals. Specifically:
| SMART Goal | Target | Outcome | Notes |
|---|---|---|---|
| Knowledge Acquisition | 90% | 92.5% achieved | Participants demonstrated strong understanding. |
| Vaccine Scheduling Commitment | 80% | 75% achieved | Many voiced intent, but some hesitated. |
| Communication Confidence | 85% | 85% achieved | Some requested further support with myth-busting. |
Challenges included reluctance among teens to commit without family consultation and discomfort tackling myths without further training. Improvements could involve in-session family engagement, structured role-plays, and extended sessions or follow-ups.
Evaluation Based on Healthy People 2030
This session also addressed the preventive goals outlined in Healthy People 2030. The focus on increasing adolescent HPV vaccination rates aligns well with national objectives (U.S. Department of Health and Human Services, n.d.).
| HP2030 Objective | Session Outcome | Recommendations |
|---|---|---|
| Increase adolescent HPV vaccination | 75% scheduled commitment, 92.5% gained knowledge | Extend family participation and follow-up efforts. |
| Reduce HPV-related cancer incidence | 85% improved communication confidence | Enhance education on vaccine safety and efficacy. |
Although the scheduling goal fell slightly short, the session’s educational value supported informed health decisions and advanced public health awareness in line with national goals.
Conclusion
In conclusion, today’s session highlighted the vital role of timely HPV vaccination in preventing cancer among adolescents and young adults in Schwenksville, PA. We made notable strides in raising awareness, enhancing communication skills, and encouraging preventive action. Guided by our SMART goals, we identified areas of strength and areas for improvement. While we approach Healthy People 2030 objectives, future sessions can build on this success to deepen community engagement and promote healthier futures through preventive care.
References
Cheng, L., Wang, Y., & Du, J. (2020). Human papillomavirus vaccines: An updated review. Vaccines, 8(3), 391. https://doi.org/10.3390/vaccines8030391
Hoes, J., Pasmans, H., Schurink-van ’t Klooster, T. M., van der Klis, F. R. M., Donken, R., Berkhof, J., & de Melker, H. E. (2021). Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge. Human Vaccines & Immunotherapeutics, 18(1). https://doi.org/10.1080/21645515.2021.1908059
Capella 4055 Assessment 4
Huber, J., Mueller, A., Sailer, M., & Regidor, P.-A. (2021). Human papillomavirus persistence or clearance after infection in reproductive age. What is the status? Review of the literature and new data of a vaginal gel containing silicate dioxide, citric acid, and selenite. Women’s Health, 17, 174550652110207. https://doi.org/10.1177/17455065211020702
Kassymbekova, F., Zhetpisbayeva, I., Tcoy, E., Dyussenov, R., Davletov, K., Rommel, A., & Glushkova, N. (2023). Exploring HPV vaccine knowledge, attitudes, barriers and information sources among parents, health professionals and teachers in Kazakhstan: A mixed-methods study protocol. BMJ Open, 13(9), e074097. https://doi.org/10.1136/bmjopen-2023-074097
PA.gov. (2025). Dear VFC provider. https://www.pa.gov/content/dam/copapwp-pagov/en/health/documents/topics/documents/programs/immunizations…
Capella 4055 Assessment 4
U.S. Department of Health and Human Services. (n.d.). Healthy People 2030: Increase the proportion of adolescents who get recommended doses of the HPV vaccine — IID‑08. https://health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination/increase-proportion-adolescents-who-get-recommended-doses-hpv-vaccine-iid-08